Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Expensive Rocket
1965.4000 -14.80 (-0.75%)
NSE Nov 18, 2026 15:54 PM
Volume: 185.9K
 

1965.40
-0.75%
Emkay
Following the slump in FY23, DLPL has registered revenue/EBITDA/PAT CAGR of 10%/19%/43%, respectively, over the last two years.
Number of FII/FPI investors increased from 357 to 427 in Sep 2026 qtr.
More from Dr. Lal Pathlabs Ltd.
Recommended